Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Ascletis raises $100mm in Series B round

Executive Summary

Ascletis Inc. raised $100mm in its Series B financing led by C-Bridge Capital, which was joined other Series A backers Goldman Sachs and Tasly Pharmaceutical and new investors including QianHai Equity Investment FOF, FOCUS Media Jiangnanchun Foundation, and WTT Investment. The company plans to use the funds for ongoing pipeline development and sales force expansion. Ascletis has been focusing on therapies for hepatitis C but now plans to move into hepatitis B and other liver diseases.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register